

**Maricopa Integrated Health Systems
Formulary Prior Auth Criteria**

Drug: Zoladex (Goserelin acetate implant)

Therapy:

Prostatic Carcinoma- indicated in the palliative treatment of advanced carcinoma of the prostate

Advanced Breast Cancer- indicated for use in the palliative treatment of advanced breast cancer in pre- and perimenopausal women (*Estrogen and progesterone receptor values may help to predict whether Zoladex therapy is likely to be beneficial*)

Inclusions

A) Prostate Cancer

What formulary medications have been tried and failed

B) Advanced Breast Cancer

What formulary medications have been tried and failed

Risk factors/Contraindications:

Males-

The use of Zoladex in patient at particular risk of developing ureteral obstruction or spinal cord compression should be carefully considered and the patients monitored closely during the first month of therapy. Patients with ureteral obstruction or spinal cord compression should have appropriate treatment prior to initiation of Zoladex therapy.

Females-

Zoladex should not be prescribed if the patient is pregnant, breast feeding, lactating, has nondiagnosed abnormal vaginal bleeding or is allergic to any of the components of Zoladex

Zoladex induces a hypoestrogenic state, which results in a loss of bone mineral density (BMD) over the course of treatment, some of, which may not be reversible

Authorization:

Initially six months with reauthorization of six months with documented efficacy

Medical Director _____

Date _____